Jump to main content
Jump to site search

Issue 31, 2018
Previous Article Next Article

Why develop photoactivated chemotherapy?

Author affiliations

Abstract

Photoactivated chemotherapy is an approach where a biologically active compound is protected against interaction with the cell environment by a light-cleavable protecting group, and unprotected by light irradiation. As such, PACT represents a major scientific opportunity for developing new bioactive inorganic compounds. However, the societal impact of this approach will only take off if the PACT field is used to address real societal challenges, i.e., therapeutic questions that make sense in a clinical context, rather than purely chemical questions. In particular, I advocate here that the field has become mature enough to switch from a compound-based approach, where a particular cancer model is chosen only to demonstrate the utility of a compound, to a disease-based approach, where the question of which disease to cure comes first: which PACT compound should I make to solve that particular clinical problem? The advantages and disadvantages of PACT vs. other phototherapeutic techniques are discussed, and a roadmap towards real clinical applications of PACT is drawn.

Graphical abstract: Why develop photoactivated chemotherapy?

Back to tab navigation

Publication details

The article was received on 20 Apr 2018, accepted on 21 Jun 2018 and first published on 23 Jun 2018


Article type: Perspective
DOI: 10.1039/C8DT01585F
Citation: Dalton Trans., 2018,47, 10330-10343
  •   Request permissions

    Why develop photoactivated chemotherapy?

    S. Bonnet, Dalton Trans., 2018, 47, 10330
    DOI: 10.1039/C8DT01585F

Search articles by author

Spotlight

Advertisements